This dataset contains summary data visualizations and clinical data from a broad sampling of 372 liver hepatocellular carcinomas from 372 patients. The data was gathered as part of the PanCancer Atlas initiative, which aims to answer big, overarching questions about cancer by examining the full set of tumors characterized in the robust TCGA dataset. The clinical data includes mutation count, information...

This dataset contains summary data visualizations and clinical data from the targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay. The clinical data includes mutation count, information about mutated genes, tumor mutational burden calculations, tissue site from which the sample was derived, tumor purity among other relevant data points. The data set also includes copy-number segment...

This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...

This dataset contains summary data visualizations and clinical data from a broad sampling of hepatocellular adenomas and carcinomas. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), Patient ID, Sample ID, Cancer Type Detailed, Mutation Count, Fraction Genome Altered, Collaboration...

This dataset contains summary data visualizations and clinical data from a broad sampling of hepatocellular carcinomas. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes mutation count, information about mutated genes, patient demographics, modality details, and disease status. The data set also includes copy-number segment data downloadable as .seg...

TCGA Liver Hepatocellular Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 442 carcinomas from 440 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...

Summary from the GEO: "Hepatocellular carcinoma (HCC) has dismal treatment responses to systemic therapies and is caused by both, viral and non-viral etiologies, including non-alcoholic steatohepatitis (NASH) 1–5. NASH - triggered by high caloric intake and sedentary lifestyle - has become an important driver for HCC development. Immunotherapy has been recently approved for HCC but stratification...

Investigating the NASH-triggered HCC in the context PD-1-targeted immunotherapy with flow cytometry, single cell RNA sequencing, immunohistochemistry and mass spectrometric analyses, we found a progressive increase of CD8+PD-1+ effector T-cells with a unique profile of exhaustion and activation markers rising with murine and human NASH severity. Notably, late-stage HCC treatment with PD-1-targeted...

Summary from the GEO: "Whereas some cancer types (e.g. melanoma) can be efficiently treated with immunotherapy, others lack measurable positive effects (e.g. PDAC ). Moreover, stratification of responders/non-responders is only possible in some cancer types (e.g. melanoma). Hepatocellular carcinoma (HCC) has a dismal prognosis, limited treatment options and survival benefit, and represents a potential...

Summary from the ENA: "Mice with advanced non alcoholic fatty liver disease (NASH) by dietary feeding regime of choline deficient high fat diet (CD-HFD) were treated with antibodies (a-CD8 depletion; a-PD1 checkpoint inhibition; Co-depletion by a-CD8 and a-NK1.1 administration) for 8 weeks. Surprisingly, a-CD8 depletion prevented hepatocarcinogenesis; in contrast a-PD1 checkpoint inhibition induced...